Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jennifer Patterson

Nurse Practitioner Brunswick, GA Nurse Practitioner

NPI 1386213122 CMS profile 11140047

3222 Shrine Rd, Brunswick, GA 31520

Open in the dashboard

General payments

$2,757

189 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Patterson of Brunswick, GA is reported in the CMS Open Payments database as having received $2,757 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $158 8
2024 General $737 48
2023 General $1,088 66
2022 General $774 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Patterson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jennifer Patterson were reported at $158. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jennifer Patterson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $774 $152 $48–$470 $149
2023 $1,088 $166 $54–$529 $160
2024 $737 $173 $55–$556 $164
2025 $158 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $610 24 payments
  2. Currax Pharmaceuticals LLC $413 32 payments
  3. Impel Pharmaceuticals Inc. $378 29 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $242 34 payments
  5. Pfizer Inc. $242 11 payments
  6. Teva Pharmaceuticals USA, Inc. $207 12 payments
  7. Tonix Pharmaceuticals, Inc. $166 17 payments
  8. Amgen Inc. $84 5 payments
  9. AstraZeneca Pharmaceuticals LP $67 4 payments
  10. Novo Nordisk Inc $42 2 payments
  11. Other $306 19 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,757 189 payments
Products named General payments · program years 2022–2025
  1. Trudhesa $378 29 payments
  2. ONZETRA XSAIL $295 23 payments
  3. QULIPTA $287 13 payments
  4. UBRELVY $273 13 payments
  5. CONTRAVE $265 19 payments
  6. NURTEC ODT Primary Care $242 34 payments
  7. NURTEC ODT Pain $242 11 payments
  8. AJOVY $207 12 payments
  9. ZEMBRACE SYMTOUCH $182 18 payments
  10. ZAVZPRET $153 10 payments
  11. Other $751 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

436

Median for Nurse Practitioner: 389

Drug cost

$115,153

Median for Nurse Practitioner: $21,885

Branded share of claims

38.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 35 $37,521
Ubrelvy Ubrogepant Brand 20 $20,076
Ajovy Autoinjector Fremanezumab-Vfrm Brand 17 $16,579
Qulipta Atogepant Brand 14 $14,584
Aimovig Autoinjector Erenumab-Aooe Brand 13 $12,130
Lamotrigine Odt Lamotrigine Brand 18 $9,346
Sumatriptan Succinate Generic 61 $1,526
Rizatriptan Rizatriptan Benzoate Brand 34 $750
Naratriptan Hcl Generic 27 $635
Gabapentin Generic 28 $481

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$22,711

Of which drugs: $10,992

Medicare patients

99

Average age 66

Services billed

2,601

66 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 45%
Depression 34%
Diabetes 19%
Ischemic heart disease 14%
Cancer 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 11 2,400 $10,725

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEMBRACE SYMTOUCH
  • TONIX PHARMACEUTICALS, INC. $166
$166 — —
UBRELVY
  • AbbVie, Inc. $104
$104 20 —
QULIPTA
  • AbbVie, Inc. $104
$104 14 —
AJOVY
  • Teva Pharmaceuticals USA, Inc. $58
$58 17 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record